Get the StoQuant digest — free

Free StoQuant digest by email. No account needed. See today's research picks.

Subscribe free

IBRX vs PHG — Stock Comparison

Compare IBRX and PHG side-by-side on StoQuant: IBRX Q-Score 46 vs PHG 58; analyst signal 60 vs 64. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.

Side-by-side snapshot

• IBRX — ImmunityBio Inc. Common Stock · Health Care · market cap $9.34B · Q-Score verdict Hold (46.0, grade C) · analyst signal 60/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: AI Alpha (gem) 93/100, technicals 82/100 · weakest signals: earnings quality 31/100, social sentiment 21/100. Full IBRX research.
• PHG — Koninklijke Philips N.V. · Health Care · market cap $25.46B · Q-Score verdict Buy (58.0, grade B) · analyst signal 64/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: technicals 72/100, analyst consensus 48/100 · weakest signals: ML forecast 15/100. Full PHG research.

What you can compare

• Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
• Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
• Insider activity: Cluster scores and recent Form 4 buying.
• Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
• Strategic edges: Competitive moat and durable advantage analysis.
• Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
• Macro context: Market regime and sector rotation alignment.

Deep dive: IBRX research · PHG research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →